Antios therapeutics and arbutus biopharma announce first patient dosed in phase 2a combination trial of ati-2173, ab-729 and tenofovir disoproxil fumarate in patients with chronic hepatitis b virus infection

Mendham, n.j. and warminster, pa., dec. 14, 2021 (globe newswire) -- antios therapeutics, inc. (“antios”) and arbutus biopharma corporation (nasdaq: abus) today announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis b virus (hbv) infection. a single cohort in the ongoing antios phase 2a save-1 (sustained anti-viral efficacy) clinical trial will evaluate a triple combination of antios' proprietary active site polymerase inhibitor nucleotide (aspin), ati-2173, arbutus' proprietary galnac delivered rnai therapeutic, ab-729, and tenofovir disoproxil fumarate (tdf), a nucleotide reverse transcriptase inhibitor.
ABUS Ratings Summary
ABUS Quant Ranking